Skip to content

Shares (Diluted) at other companies

Pfizer logo
PfizerPFE
5.7B+0.4%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
45.1M+32.9%
CG Oncology logo
CG OncologyCGON
84.5M+10.9%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
102.8M+20.3%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
15.6M+0.8%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
63.1M+6.2%

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.0%
Enterprise value$923.07M+23.5%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0.0×
Current ratio16.3×+4.3×

Where this comes from

Reported directly by Oric Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s shares (diluted)?
Oric Pharmaceuticals, Inc. (ORIC) reported shares (diluted) of 105.5M in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s shares (diluted) changed year-over-year?
Oric Pharmaceuticals, Inc.'s shares (diluted) increased by 48.5% year-over-year, from 71M to 105.5M.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s shares (diluted)?
Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s shares (diluted) has grown at a 22.3% compound annual growth rate (CAGR), from 150.3M to 335.9M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.